Diffuse large B-cell lymphoma (DLBCL) is the most common type of lymphoma and is
notorious for its heterogeneity, aggressive nature, and the frequent development of …

Despite considerable advances in the treatment of lymphoma, the prognosis of patients with
relapsed and/or refractory disease continues to be poor; thus, a continued need exists for …

D-type cyclins are central regulators of the cell division cycle and are among the most
frequently deregulated therapeutic targets in human cancer, but the mechanisms that …

EZH2, the catalytic subunit of the PRC2 complex, catalyzes the mono-through trimethylation
of lysine 27 on histone H3 (H3K27). Histone H3K27 trimethylation is a mechanism for …

Background Diffuse large B-cell lymphoma (DLBCL) is an aggressive and complex disease
characterized by wide clinical, phenotypic and molecular heterogeneities. The expression …

The methylcytosine dioxygenase TET1 ('ten-eleven translocation 1') is an important
regulator of 5-hydroxymethylcytosine (5hmC) in embryonic stem cells. The diminished …

EZH2 is the catalytic subunit of the PRC2 Polycomb complex and mediates transcriptional
repression through its histone methyltransferase activity. EZH2 is up-regulated in normal …

Although aberrant DNA methylation patterning is a hallmark of cancer, the relevance of
targeting DNA methyltransferases (DNMT) remains unclear for most tumors. In diffuse large …

Richter syndrome (RS) is the transformation of chronic lymphocytic leukemia (CLL) into
aggressive lymphoma, most commonly diffuse large B-cell lymphoma (DLBCL). We …

Diffuse large B cell lymphomas (DLBCLs) are genetically heterogeneous and highly
proliferative neoplasms derived from germinal center (GC) B cells. Here, we show that …